JD Supra: Mergers

DECEMBER 1, 2023

To that end, the DOJ recently announced its decision to decline to prosecute Lifecore Biomedical, a pharmaceutical and medical device manufacturer, despite evidence that employees of Lifecore’s former US subsidiary bribed Mexican government officials in violation of the Foreign Corrupt Practices Act.

M&A 167

M&A Pharmaceutical Medical Manufacturing 167

Global Newswire by Notified: M&A

OCTOBER 4, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals.

Pharmaceutical 49

Pharmaceutical Mergers 49

Global Newswire by Notified: M&A

MARCH 20, 2024

Nika Pharmaceuticals, Inc. OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.

Pharmaceutical 89

Pharmaceutical Mergers IT 89

Sun Acquisitions

AUGUST 22, 2024

To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A).

M&A 52

M&A Management Mergers and Acquisitions Food 52

Global Newswire by Notified: M&A

MAY 13, 2024

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology

Mergers 53

Mergers Pharmaceutical Portfolio 53

JD Supra: Mergers

APRIL 23, 2024

I moderated a panel, “Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics.

Pharmaceutical 167

Pharmaceutical M&A Sale Investors 167

Global Newswire by Notified: M&A

JULY 9, 2024

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger

Mergers 61

Mergers Pharmaceutical Stock 61

Devensoft

JUNE 19, 2023

Mergers and acquisitions (M&A) constitute intricate and frequently risky transactions with significant implications for stakeholders. That’s why companies need to approach M&A deals with a strategic mindset that minimizes risk and maximizes value.

M&A 52

M&A Mergers and Acquisitions Mergers Management 52

Global Newswire by Notified: M&A

OCTOBER 6, 2023

PRESIDIO PROPERTY TRUST ANNOUNCES CLOSING OF MERGER OF ITS SPONSORED SPAC MURPHY CANYON ACQUISITION CORP NOW TRADING AS CONDUIT PHARMACEUTICALS.

Pharmaceutical 40

Pharmaceutical Mergers and Acquisitions Mergers Trading 40

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 64

M&A Pharmaceutical Acquisitions Valuation 64

Devensoft

AUGUST 22, 2023

Embracing Innovation in M&A Strategies As the M&A landscape evolves, the call for innovation grows louder. Enter freelance modeling—a dynamic concept that adapts M&A to the fast-paced, unpredictable realm of modern business. In the upcoming sections, we explore how freelance modeling reshapes M&A norms.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Solganick & Co.

SEPTEMBER 2, 2024

September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. The Top Software M&A Transactions Announced so far in 2024 include: January 2024: Synopsys announced a $31.9

Mergers and Acquisitions 52

Mergers and Acquisitions Acquisitions Mergers M&A 52

Global Newswire by Notified: M&A

OCTOBER 2, 2024

– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., 02, 2024 (GLOBE.

Pharmaceutical 45

Pharmaceutical Mergers Stock Trading 45

Global Newswire by Notified: M&A

AUGUST 15, 2023

Reverse Stock Split Merger on Track to Close on August 16, 2023 Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5

Mergers 40

Mergers Pharmaceutical Stock 40

Global Newswire by Notified: M&A

SEPTEMBER 11, 2024

ANI and Alimera Scheduled the Closing for September 16, 2024 ANI and Alimera Scheduled the Closing for September 16, 2024

Pharmaceutical 56

Pharmaceutical Mergers 56

Global Newswire by Notified: M&A

JULY 23, 2024

The Company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024.

Mergers 40

Mergers Pharmaceutical Medical IT 40

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

The Harvard Law School Forum

JUNE 16, 2023

Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Flanagan are Partners and Hannah M. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? Brown is an Associate at Sidley Austin LLP.

M&A 40

M&A Pharmaceutical Acquisitions Valuation 40

Software Equity Group

JUNE 6, 2023

A key indicator is the increasing number of SaaS M&A transactions as companies seek to expand into new markets, consolidate current markets, provide end-to-end solutions, and take advantage of synergies. As a trusted partner in SaaS M&A, we are thrilled to have played a pivotal role in these significant deals.

M&A 52

M&A Mergers and Acquisitions Middle Market Acquisitions 52

Devensoft

MAY 25, 2023

Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. We, at Devensoft, help companies with their end-to-end M&A and have worked with several clients in the corporate sector to navigate this complex process.

Corporation 52

Corporation Mergers Mergers and Acquisitions Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

How2Exit

MARCH 31, 2024

Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?

Business 130

Business Mergers and Acquisitions Securities M&A 130

Global Newswire by Notified: M&A

NOVEMBER 6, 2024

TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. billion.

Capital 75

Capital Pharmaceutical Manufacturing Funds 75

Cooley M&A

FEBRUARY 8, 2018

What’s on tap for 2018 M&A? One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. A recap of 2017 trends and the Cooley outlook on this year’s dealmaking: Buying Innovation: Retention and Non-Competes.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Cooley M&A

JANUARY 22, 2021

General Trends in Life Sciences M&A. In contrast, aggregate M&A deal value for the life sciences sector was down nearly 50% when compared to 2019, with the first half of 2020 particularly dismal in the wake of market uncertainty caused by the pandemic.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Global Newswire by Notified: M&A

APRIL 11, 2024

Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd.

Pharmaceutical 53

Pharmaceutical Mergers IT 53

M&A Leadership Council

SEPTEMBER 26, 2024

Assessing Your Fit for the Role of Integration Management Office Lead By M&A Leadership Council In M&A, the Integration Management Office (IMO) Lead plays a critical role in ensuring a smooth, efficient integration process. The position requires strategic insight, operational knowledge, and strong leadership.

Mergers and Acquisitions 52

Mergers and Acquisitions M&A Management Mergers 52

Cooley M&A

OCTOBER 24, 2024

While this mantra may help bruised egos on the playground, it’s of no use in M&A disputes. Alexion Pharmaceuticals (Del. After lengthy negotiations, a J&J entity and Auris entered into a merger agreement in February 2019, with J&J agreeing to pay $3.4 In both Fortis v. Johnson & Johnson (Del.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Negotiation Sale 52

Shearman & Sterling

SEPTEMBER 6, 2016

Bouchard of the Delaware Court of Chancery dismissed a shareholder action seeking post-merger damages for breach of fiduciary duty against the directors and officers of C&J Energy Services, Inc. Slights III of the Delaware Court of Chancery dismissed an action brought by former shareholders of Auspex Pharmaceuticals, Inc.

Mergers 52

Mergers Pharmaceutical M&A Business 52

Shearman & Sterling

SEPTEMBER 6, 2016

Bouchard of the Delaware Court of Chancery dismissed a shareholder action seeking post-merger damages for breach of fiduciary duty against the directors and officers of C&J Energy Services, Inc. Slights III of the Delaware Court of Chancery dismissed an action brought by former shareholders of Auspex Pharmaceuticals, Inc.

Mergers 40

Mergers Pharmaceutical M&A Business 40

M&A Leadership Council

AUGUST 15, 2022

Fundamentals of M&A: An Excerpt from The Art of M&A Book Series. By Alexandra Reed Lajoux, Board of M&A Standards/Founding Principal at CapEx . Sometimes spin-offs precede mergers. How Common are Postmerger Divestitures of Acquired Company Units? . Yet in major companies, the level appears to be lower.

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

InvestmentBank.com

AUGUST 14, 2019

The benefits of VR are not limited to language immersion, architecture, interior design, space expedition, biology, chemistry or pharmaceutical practices. Students (K-12) participating in schools with technological integration efforts achieved an increase of 94 points on average in SAT I performance [1]. billion in 2018 in the U.S.,

Education 52

Education Mergers and Acquisitions Capital Investment 52

The Deal

NOVEMBER 19, 2023

It’s not uncommon to see a big-ticket M&A deal get stifled after a deal announcement. While the issue has been intensifying over the past decade, in July the Biden administration proposed new merger guidelines to further protect competition. carve-outs or divestitures) before entering a merger agreement.

M&A 59

M&A Mergers Pharmaceutical IT 59

Cooley M&A

NOVEMBER 25, 2020

Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed.

Pharmaceutical 40

Pharmaceutical Media Mergers 40

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. The Merger Agreement. 2018-0300-JTL (Del.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Cooley M&A

JANUARY 24, 2018

Read on to see how these trends may affect your business.

Pharmaceutical 52

Pharmaceutical Mergers Business 52